Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H22FNO.ClH |
Molecular Weight | 299.811 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1
InChI
InChIKey=MQHYXXIJLKFQGY-UHFFFAOYSA-N
InChI=1S/C16H22FNO.ClH/c1-13-8-11-18(12-9-13)10-2-3-16(19)14-4-6-15(17)7-5-14;/h4-7,13H,2-3,8-12H2,1H3;1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C16H22FNO |
Molecular Weight | 263.3504 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
CNS Activity
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | MELPERON Approved UseMelperon is used to treat sleep disorders, confusion states, and to suppress psychomotor restlessness and excitement, especially in geriatric and psychiatric patients. |
|||
Primary | MELPERON Approved UseMelperon is used to treat sleep disorders, confusion states, and to suppress psychomotor restlessness and excitement, especially in geriatric and psychiatric patients. |
|||
Primary | MELPERON Approved UseMelperon is used to treat sleep disorders, confusion states, and to suppress psychomotor restlessness and excitement, especially in geriatric and psychiatric patients. |
PubMed
Title | Date | PubMed |
---|---|---|
A comparison of two doses of melperone, an atypical antipsychotic drug, in the treatment of schizophrenia. | 2003 Jul 1 |
|
Screening, library-assisted identification and validated quantification of fifteen neuroleptics and three of their metabolites in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization. | 2003 Mar |
|
P-glycoprotein is a factor in the uptake of dextromethorphan, but not of melperone, into the mouse brain: evidence for an overlap in substrate specificity between P-gp and CYP2D6. | 2004 Dec |
|
[The case of a 86-years old woman first diagnosed with Huntington's disease]. | 2004 Nov |
|
The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). | 2008 Dec 22 |
|
[Recurrent dysregulation of body temperature during antipsychotic pharmacotherapy]. | 2008 Mar |
|
Changes in weight and body mass index during treatment with melperone, clozapine and typical neuroleptics. | 2010 Apr 30 |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
Patents
Sample Use Guides
The recommended dose of melperone (in form of hydrochloride salt) is 25-75 mg/day. In the case of restless and confused patients the drug is given at a dose of 50-100 mg at the beginning of the treatment. The dose can be increased up to 200 mg if necessary. In severe disorders of confusion and confusion with aggression and hallucinatory conditions, the daily dose can be increased to up to 400 mg melperone HCl.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:25:35 GMT 2023
by
admin
on
Fri Dec 15 15:25:35 GMT 2023
|
Record UNII |
88G640374K
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
289623
Created by
admin on Fri Dec 15 15:25:35 GMT 2023 , Edited by admin on Fri Dec 15 15:25:35 GMT 2023
|
PRIMARY | RxNorm | ||
|
m7165
Created by
admin on Fri Dec 15 15:25:35 GMT 2023 , Edited by admin on Fri Dec 15 15:25:35 GMT 2023
|
PRIMARY | Merck Index | ||
|
C008522
Created by
admin on Fri Dec 15 15:25:35 GMT 2023 , Edited by admin on Fri Dec 15 15:25:35 GMT 2023
|
PRIMARY | |||
|
760102
Created by
admin on Fri Dec 15 15:25:35 GMT 2023 , Edited by admin on Fri Dec 15 15:25:35 GMT 2023
|
PRIMARY | |||
|
SUB14503MIG
Created by
admin on Fri Dec 15 15:25:35 GMT 2023 , Edited by admin on Fri Dec 15 15:25:35 GMT 2023
|
PRIMARY | |||
|
15386
Created by
admin on Fri Dec 15 15:25:35 GMT 2023 , Edited by admin on Fri Dec 15 15:25:35 GMT 2023
|
PRIMARY | |||
|
216-599-9
Created by
admin on Fri Dec 15 15:25:35 GMT 2023 , Edited by admin on Fri Dec 15 15:25:35 GMT 2023
|
PRIMARY | |||
|
88G640374K
Created by
admin on Fri Dec 15 15:25:35 GMT 2023 , Edited by admin on Fri Dec 15 15:25:35 GMT 2023
|
PRIMARY | |||
|
DTXSID10936649
Created by
admin on Fri Dec 15 15:25:35 GMT 2023 , Edited by admin on Fri Dec 15 15:25:35 GMT 2023
|
PRIMARY | |||
|
1622-79-3
Created by
admin on Fri Dec 15 15:25:35 GMT 2023 , Edited by admin on Fri Dec 15 15:25:35 GMT 2023
|
PRIMARY | |||
|
100000092068
Created by
admin on Fri Dec 15 15:25:35 GMT 2023 , Edited by admin on Fri Dec 15 15:25:35 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |